NL-OMON56484
Not yet recruiting
Not Applicable
Predict Response Of Drugs In Ovarian Cancer Treatment Using Organoids - PRODICT
niversitair Medisch Centrum Utrecht0 sites239 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- epithelial ovariancarcinoma
- Sponsor
- niversitair Medisch Centrum Utrecht
- Enrollment
- 239
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •To be eligible to participate in this study, a subject must meet all of the
- •following criteria:
- •1\. Patients diagnosed with (the suspicion of) epithelial ovarian carcinoma
- •amenable for standard\-of\-care systemic treatment in the adjuvant or recurrent
- •setting, including, but not limited to:
- •Treatment for primary advanced stage EOC:
- •1\.1\. Carboplatin/paclitaxel \+ PARP inhibitor\* (including repeated cycles)
- •1\.2\. Carboplatin/gemcitabine \+ PARP inhibitor\* (only if not administered yet)
- •1\.3\. Carboplatin/gemcitabine \+ bevacizumab (including repeated cycles)
- •Treatment for recurrent advanced stage EOC:
Exclusion Criteria
- •Patients with unrelated secondary tumors that in the opinion of the
- •investigator interfere with treatment decision making, affect response
- •evaluation of pose a competing risk for survival.
- •Patients who underwent a diagnostic biopsy due to suspicion of EOC, but
- •histological examination did not confirm this diagnosis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Search for Predictors of Therapeutic Response in Ovarian CarcinomaCarcinoma of the OvaryFallopian Tube CancerPeritoneal Serous-type Advanced StageNCT01391351Centre Francois Baclesse107
Terminated
Not Applicable
Improving communication about treatment options for asymptomatic ovarian cancer patients with rising cancer antigen 125 (CA-125): A randomised controlled trial of a Decision AidCommunication about treatment options and decision making for women with asymptomatic ovarian cancer and rising CA-125 levels.Cancer - Ovarian and primary peritonealACTRN12609001035213Centre for Medical Psychology and Evidence-based Decision-making178
Not yet recruiting
Not Applicable
Comparising result of histopathology examination to frozen section for diagnosing ovarian malignancyHealth Condition 1: C569- Malignant neoplasm of unspecifiedovaryCTRI/2024/04/065770JAWAHAR LAL NEHRU MEDICAL COLLEGE
Completed
Not Applicable
Early detection of ovarian cancer and response prediction: TEP and ctDNA study.NL-OMON50170Catharina-ziekenhuis200
Completed
Not Applicable
Evaluation of HE4 in ovarian cancerOvarian cancerJPRN-UMIN000037812ihon University Hospital59